The company recently urged shareholders to approve the deal, saying the cash consideration they'd receive would represent a premium over recent stock prices.
The institute has selected the firm's RNA-seq library preparation kits for use in gene expression profiling in single-cell analysis of brain cells.
The single-cell analysis firm told shareholders that while the final offer from Takara is not set in stone, they're unlikely to be offered better terms.
Last month, the companies announced that Takara Bio USA — formerly Clontech Laboratories and now a subsidiary of Japan's Takara Bio — would acquire WaferGen.
Takara said it will pay an aggregate cash purchase price that will be based on a multiple of WaferGen's 2016 revenues, capped at $50 million.
The companies will combine their respective technologies and expertise to develop new products for low-input, targeted RNA-seq applications.
The method was developed in the laboratory of Rickard Sandberg at the Ludwig Institute for Cancer Research in Stockholm and published by his group in 2013.
NEW YORK (GenomeWeb News) — Genedata announced today that Takara Bio has chosen the Genedata Expressionist software platform for use in all its genomics, transcriptomics, and epigenomics research.
NEW YORK (GenomeWeb) – Cellectis today announced it is selling its stem cell-focused subsidiary Cellectis AB to Takara Bio for an undisclosed amount.
NEW YORK (GenomeWeb News) – Invivoscribe Technologies today said that a German court has ruled in its favor in a patent dispute over FLT3 testing technology.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.